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provided it is propeObjective: To assess, among people with HIV, the association of self-reported
antiretroviral treatment (ART) and viral load status with condomless sex with an
HIV-serodifferent partner (CLS-D).
Design: Cross-sectional study of 3258 HIV-diagnosed adults in the United Kingdom,
2011–2012.
Methods: CLS-D in the past 3 months and self-reported ART/viral load were ascertained
by questionnaire. Clinic-recorded viral load was documented. HIV-transmission risk
sex (CLS-D-HIV-risk) was defined as CLS-D together with either not on ART or clinic-
recorded viral load more than 50 copies/ml.
Results: Of 3178 participants diagnosed more than 3 months ago, 2746 (87.9%) were
on ART, of whom self-reported viral load was ‘50 copies/ml/ or less/undetectable’ for
78.4%; ‘more than 50 copies/ml/detectable’ for 8.3%; ‘do not know/missing’ for 13.3%.
CLS-D prevalence was 14.9% (326/2189), 6.4% (23/360) and 10.7% (67/629) among
men who have sex with men, heterosexual men and women, respectively. Among men
who have sex with men, CLS-D prevalence was 18.8% among those not on ART; 15.2%
among those on ART with undetectable self-reported viral load; 9.8% among those
on ART without undetectable self-reported viral load. Compared with ‘on ART with
undetectable self-reported viral load’, prevalence ratios (95% confidence interval)
adjusted for demographic/HIV-related factors were: 0.66 (0.45, 0.95) for ‘on ART
without undetectable self-reported viral load’, and 1.08 (0.78, 1.49) for ‘not
on ART’ (global P¼0.021). Among heterosexual men and women (combined),
ART/self-reported viral load was not associated with CLS-D [corresponding adjusted
prevalence ratios: 1.14 (0.73, 1.79) for ‘on ART without undetectable self-reported viral
load’; 0.88 (0.44, 1.77) for ‘not on ART’, P¼0.77]. CLS-D-HIV-risk prevalence was
3.2% among all participants; 16.1% for ‘not on ART’; 0.6% for ‘on ART with
undetectable self-reported viral load; 4.2% for ‘on ART without undetectable self-
reported viral load.’
Conclusion: Use of ART was not associated with increased prevalence of CLS-D, and
was associated with greatly reduced prevalence of HIV-transmission risk sex.
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Transmission of HIV in the United Kingdom continues
to be high among men who have sex with men (MSM)
[1–3]. Among heterosexual men and women, trans-
mission within the United Kingdom is also ongoing,
despite a decline in overall number of new diagnoses
because of migration patterns [1]. Although it is estimated
that most new HIV infections in the United Kingdom are
transmissions from people unaware that they have HIV
[3,4], a significant proportion (an estimated 18% among
MSM [3]) are transmissions from people already
diagnosed, indicating that prevention issues in this group
remain important. Understanding patterns of sexual
behaviour according to antiretroviral treatment (ART)
use among people diagnosed with HIV has implications
for clinical care and public health.
Recommendations on when (at what CD4þ cell count)
an individual with HIV should start ART have shifted,
over time, towards earlier initiation of ART. For some
years, interest has focused on a strategy of offering ART to
all people with HIV, from diagnosis, irrespective of CD4þ
cell count [4,5], and such a policy was recommended in
the United States in 2012 [6]. Until very recently, the
main impetus for this strategy was the potential impact on
transmission, based on compelling results regarding the
profound reduction in infectiousness to sexual partners
for HIV-positive people taking ARTwith suppressed viral
load [7–13], in particular from the HPTN052 trial in
2011 [12], and the recent PARTNER study [13]. In May
2015, landmark results of the international START trial
demonstrated that earlier ART also confers clinical
prognostic benefit to the individual [14]. Consequently,
treatment guidelines worldwide are being changed to
recommend immediate ART for all people diagnosed
with HIV [15,16]. Such a strategy should reduce HIV-
related morbidity, and reduce HIV transmission.
A longstanding question is whether taking ART may
influence an individual’s sexual behaviour. This question
is becoming increasingly relevant, as knowledge about the
protective effect of ARTon HIV infectiousness becomes
established and widespread. The ‘Swiss statement’ [17] in
2008 marked the first fundamental change in advice about
‘safe sex’ for HIV-positive people, asserting (with caveats)
that an HIV-positive person on ART with viral
suppression is not sexually infectious. Subsequent results
from the Swiss HIV Cohort study suggested higher
levels of condomless sex (CLS) with stable partners of
HIV-negative/unknown status among participants who
were virally suppressed [18]. However, most studies
carried out before [19–29] and soon after [30–33] the
Swiss Statement have not found higher prevalence of
CLS among people on ART or those with viral load
suppression. There have been few studies of sexual
behaviour among people with HIV in the United
Kingdom since the Swiss statement, and none that haveexamined associations of CLS with perceived (self-
reported) viral load status – the crucial measure when
considering impact on behaviour.
If ART use or perceived suppressed viral load was found
to be associated with substantially higher levels of
condomless sex (CLS), this could undermine the full
impact of early ART on HIV transmission. This could
occur if individuals on ARTwere not accurately assessing
their viral load status (and therefore infectiousness to
sexual partners) and modifying sexual behaviour accord-
ingly. Also of importance is that lower condom use among
people on ART may have an adverse effect on
transmission of sexually transmitted infections other than
HIV (STIs), the infectivity of which would not be
lessened by ART use. Occurrence of STIs is high among
HIV-diagnosed MSM [34,35].
The Antiretrovirals, Sexual Transmission Risk and
Attitudes (ASTRA) study investigated sexual behaviour
among people with HIV in the United Kingdom, and
aimed to address the hypothesis that ART use and
perceived undetectable viral load may be linked to CLS.
This report assesses the association of self-reported
ART/viral load status with CLS, in particular CLS with
an HIV-serodifferent partner. In addition, as the
protective effect of suppressed viral load on HIV
infectiousness is now known with confidence, this report
is the first to describe likely levels of CLS carrying an
appreciable risk of HIV transmission (accounting for
clinic-documented viral load level) according to self-
reported ART/viral load. Although attitudes and
behaviour in relation to condom use may be changing
rapidly, as knowledge about transmission risk is dis-
seminated and develops, the ASTRA results will also be
important in establishing a baseline against which findings
of future studies of HIV-positive people can be evaluated.Methods
ASTRA recruited adults with diagnosed HIV attending
eight hospital HIV outpatient clinics in the United
Kingdom from February 2011 to December 2012. Full
details have been described [36]. Participants self-
completed a confidential sex-specific questionnaire on
socio-demographic, HIV-related, health and lifestyle
factors, and sexual behaviour. The latest documented
viral load and CD4þ cell count results that the participant
had been informed of were collected from medical
records. The study was approved by North West London
REC 2 research ethics committee (ref 10/H0720/70). At
the time of the study, the British HIV Association
guidelines recommended ART initiation for HIV-
positive people with a CD4þ cell count of 350 cells/ml
or less, unless special circumstances indicated earlier ART
[37].
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Participants were asked about ever and current ART use.
Those who ever started ARTwere asked their viral load at
the last test, with three options: ‘50 copies/ml or less
(undetectable or suppressed)’; ‘more than 50 copies/ml
(detectable or raised)’ and ‘don’t know’. Self-reported
ART/viral load was categorised into three groups: not on
ART; on ARTwith undetectable self-reported viral load;
on ART without undetectable self-reported viral load
(including ‘do not know’ and missing self-reported viral
load).
Sexual behaviour
The men’s questionnaire asked about sex with women,
and sex with men; the women’s questionnaire asked about
sex with men. Participants were asked whether, in the past
3 months, they had: anal or vaginal sex (and if so how
many partners), sex without a condom (CLS), CLS with
an HIV-positive person, CLS with an HIV-serodifferent
(negative or unknown status) partner (CLS-D). Those
reporting CLS-D were asked: number and type (long-
term or other) of CLS-D partner(s); number of times had
CLS-D (in categories); whether they ever ejaculated
inside a partner during CLS-D (men only); position for
anal CLS-D for MSM (always insertive; always receptive;
both); reasons for not using a condom at last CLS-D (11
options including: ‘I believe the risk of HIV transmission
is very low’). Those who reported CLS, but did not
indicate HIV status of partner(s), were classified as having
‘possible CLS-D’, but not included in the main
definition. All participants were asked about group sex
and new STI diagnoses in the past 3 months, and number
of new sexual partners in the past year.
HIV-transmission risk sex
A variable was constructed to define sex with an
appreciable risk of HIV transmission (CLS-D-HIV-risk).
CLS-D-HIV-risk is a subset of CLS-D. An individual was
positive for CLS-D-HIV-risk if, in addition to reporting
CLS-D, they were either not on ART (self-reported) or
had clinic-recorded viral load more than 50 copies/ml
(using the single viral load documented for each
participant). Individuals who reported CLS-D, but were
on ART with clinic-recorded viral load 50 copies/ml or
less were negative for CLS-D-HIV-risk.
Transmission risk beliefs
Participants rated their agreement (strongly agree, tend
to agree, undecided/no opinion, tend to disagree and
strongly disagree) with the following statements: ‘An
undetectable HIV viral load makes someone less
infectious to a sexual partner than if they had a high
viral load’ and ‘When viral load is undetectable, a condom
is not needed to prevent HIV transmission’.
Statistical analysis
Individuals who reported an HIV diagnosis date less than
3 months before the date of questionnaire issue wereexcluded, to ensure reported sexual behaviour related to a
period after diagnosis. Men who self-identified as gay or
bisexual or reported sex with a man in the past 3 months
were classified as MSM. Characteristics and sexual
behaviour were summarised for: MSM, heterosexual
men, women. Subsequent analyses were conducted
separately for MSM and all heterosexual individuals.
The combined heterosexual category was used to increase
power; there was no evidence that associations differed
between men and women. Unadjusted associations of
self-reported ART/viral load and other factors with CLS-
D, and CLS overall, were assessed using x2 tests. Modified
Poisson regression [38] was used to obtain unadjusted and
adjusted prevalence ratios with 95% confidence intervals
(CI), for association of self-reported ART/viral load with
CLS-D. First, adjustment was made for socio-demo-
graphic and HIV-related factors: age group (<30 years;
30 years); black ethnicity (no/missing; yes); university
education (no/missing; yes); identifying with a religion
(no/missing; yes); time with diagnosed HIV (3 months to
1.9 years; 2–4.9 years; 5–9.9 years; 10–14.9 years; 15–
19.9 years; 20 years) and partner status (HIV-positive;
HIV-negative/unknown status; no stable partner). Age
was used in two categories only because of collinearity
with time with diagnosed HIV. In a second model,
additional adjustment was made for higher alcohol intake
(no/missing; yes, using score 6 on the first two WHO
AUDIT-C [39] questions) and number of recreational
drugs used in the past 3 months (none/missing; 1; 2–3;
4) [40]. In heterosexual models, categories were
collapsed for some variables (see Table 4) and there
was additional adjustment for sex. Model results were not
materially altered by further adjustment for clinic, or
when cases that had been excluded because of missing
values in age, diagnosis date, partner status or self-
reported ART/viral load were included using ‘missing’
categories. The prevalence of CLS-D-HIV-risk was
described overall, and for MSM, and heterosexual men
and women, according to self-reported ART/viral load.
Three sensitivity analyses were performed separately for
MSM and heterosexual individuals. The association of
self-reported ART/viral load with CLS-D was assessed:(a) including ‘possible CLS-D’ cases;(b) excluding participants who reported no sex in the past 3
months;(c) separately among those diagnosed with HIV for less than
5 years and 5 years or more.Results
Overall, 3258 people with diagnosed HIV participated in
ASTRA (5112 invited: response rate 64%), of whom 80
are excluded as they had been diagnosed for less than
3 months. Table 1 shows characteristics for the 3178
included participants (2189 MSM, 360 heterosexual men
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Table 1. Characteristics of 3178 individuals diagnosed with HIV more than 3 months ago, according to gender/sexual orientation.
MSM, N¼2189 Heterosexual men, N¼360 Women, N¼629
N¼3178 n (%) n (%) n (%)
Age group (years), N¼3112
<30 96 (4.4) 9 (2.6) 54 (9.1)
30–39 487 (22.5) 59 (16.9) 174 (29.2)
40–49 929 (42.9) 160 (45.7) 255 (42.9)
50–59 503 (23.2) 86 (24.6) 88 (14.8)
60 152 (7.0) 36 (10.3) 24 (4.0)
Ethnicity, N¼3178d
White 1931 (88.2) 113 (31.4) 123 (19.6)
Black African 21 (1.0) 179 (49.7) 401 (63.8)
Black other 54 (2.5) 25 (6.9) 44 (7.0)
Other/missing 183 (8.4) 43 (11.9) 61 (9.7)
UK birth, N¼3105
Yes 1532 (70.9) 96 (27.7) 112 (18.7)
No 629 (29.1) 250 (72.3) 486 (81.3)
Education, N¼3178d
University 954 (43.6) 129 (35.8) 195 (31.0)
Other/missing 1235 (56.4) 231 (64.2) 434 (69.0)
Employment status, N¼3097
Employed (full or part time) 1326 (61.6) 158 (46.1) 282 (47.0)
Unemployed 309 (14.3) 94 (27.4) 160 (26.7)
Not working because of sickness/disability 316 (14.7) 38 (11.1) 62 (10.3)
Other (student, looking after home, retired, other) 203 (9.4) 53 (15.5) 96 (16.0)
Money for basic needs? N¼3116
Always 1116 (51.6) 100 (28.8) 130 (21.5)
Mostly 597 (27.6) 79 (22.8) 147 (24.3)
Sometimes 277 (12.8) 101 (29.1) 178 (29.4)
No 173 (8.0) 67 (19.3) 151 (24.9)
Identifies with a religion, N¼3178d
Yes 934 (42.7) 282 (78.3) 551 (87.6)
No/missing 1255 (57.3) 78 (21.7) 78 (12.4)
Time with diagnosed HIV, N¼3150
3 months to 1.9 years 184 (8.5) 45 (12.7) 64 (10.4)
2–4.9 years 338 (15.5) 63 (17.7) 97 (15.7)
5–9.9 years 550 (25.3) 111 (31.3) 232 (37.5)
10–14.9 years 461 (21.2) 69 (19.4) 117 (18.9)
15–19.9 years 376 (17.3) 45 (12.7) 67 (10.8)
20 years 268 (12.3) 22 (6.2) 41 (6.6)
Partner status, N¼3154
HIVþ stable partner 512 (23.6) 111 (31.1) 123 (19.7)
HIV or HIV-unknown status stable partner 674 (31.0) 133 (37.3) 220 (35.3)
No stable partner 987 (45.4) 113 (31.7) 281 (45.0)
Current smoker, N¼3178d
No/missing 1377 (62.9) 252 (70.0) 562 (89.4)
Yes 812 (37.1) 108 (30.0) 67 (10.7)
Higher alcohol consumptiona, N¼3178d
No/missing 1821 (83.2) 317 (88.1) 616 (97.9)
Yes 368 (16.8) 43 (11.9) 13 (2.1)
Number of recreational drugs used in past 3 monthsb, N¼3178d
None/missing 1078 (49.2) 303 (84.2) 585 (93.0)
1 364 (16.6) 36 (10.0) 36 (5.7)
2–3 403 (18.4) 21 (5.8) 7 (1.1)
4 344 (15.7) 0 (0) 1 (0.2)
Self-reported ART status, N¼3125
Never taken ART 253 (11.7) 19 (5.4) 42 (6.9)
Stopped ART 34 (1.6) 5 (1.4) 26 (4.3)
On ART 1876 (86.7) 327 (93.2) 543 (88.9)
Self-reported viral load status, N¼2746 on ART only
50 copies/ml or less (undetectable or suppressed) 1569 (83.6) 201 (61.5) 384 (70.7)
More than 50 copies/ml (detectable or raised) 153 (8.2) 32 (9.8) 42 (7.7)
Do not know 135 (7.2) 76 (23.2) 90 (16.6)
Missing 19 (1.0) 18 (5.5) 27 (5.0)
Clinic-recorded viral loadc (copies/ml), N¼3157
50 1694 (77.9) 281 (78.7) 486 (77.8)
>50 481 (22.1) 76 (21.3) 139 (22.2)
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Table 1 (continued )
MSM, N¼2189 Heterosexual men, N¼360 Women, N¼629
N¼3178 n (%) n (%) n (%)
Clinic-recorded CD4þ cell count c (cells/ml), N¼3155
<200 77 (3.5) 38 (10.7) 34 (5.4)
200–349 240 (11.0) 80 (22.5) 86 (13.8)
350–499 538 (24.7) 80 (22.5) 154 (24.6)
500 1320 (60.7) 157 (44.2) 351 (56.2)
aScore of 6 or more on modified WHO AUDIT C questionnaire (using first two questions only).
bParticipants selected from a list of 18 with ‘other’ option. Includes LSD, anabolic steroids, cannabis, cocaine, crack, codeine, methamphetamine,
ecstasy, GHB, herion, ketamine, khat, mephedrone, morphine, opium, nitrites, amphetamine and recreational Viagra.
cLatest clinic-recorded value that participant had been informed of. Clinic viral load was median (IQR) of 10 (3–18) weeks prior to questionnaire.
dNumber of missing values included ranges from 28 to 83.and 629 women). The vast majority reported being on
ART: 1876 (86.7%) MSM, 327 (93.2%) heterosexual
men and 543 (88.9%) women, of whom 83.6, 61.5 and
70.7% respectively had undetectable self-reported viral
load. These differences in self-reported viral load among
participants on ARTwere primarily because of the higher
proportion of heterosexual men (23.2%) and women
(16.6%) than MSM (7.2%) who did not know their viral
load status. A small proportion of participants (n¼ 65;
2.0%) reported having stopped ART. Overall 696 (22.1%)
participants (12.4% of those on ART) had clinic-recorded
viral load more than 50 copies/ml using the study-
documented viral load.
Sexual behaviour and association with self-
reported antiretroviral treatment/viral load
among men who have sex with men
Table 2 shows sexual behaviour among 2189 MSM. In the
past 3 months, 1392 (63.6%) MSM had anal/vaginal sex
(1360 with men only, 12 with women only and 20 with
both men and women), the majority of whom had more
than one partner, with over a quarter having 5 partners or
more. Overall, 836 (38.2%) MSM reported CLS; 326
(14.9%) reported CLS-D. When ‘possible CLS-D’ was
included, prevalence rose to 16.3% (n¼ 357). Of MSM
having CLS-D, most (57.5%) reported a single CLS-D
partner, whereas approximately 14% had 5 or more
CLS-D partners. For the majority (76.1%) of men
reporting CLS-D, this was sex with partners other than,
or in addition to, a long-term partner. Of men having
CLS-D, less than a third reported insertive anal CLS-D
with ejaculation inside a partner, and 40% reported
receptive anal CLS-D only. MSM who reported CLS-D
had higher prevalence of self-reported STI (22.4% vs.
8.7%) and group sex (45.1% vs. 16.4%) than those who
did not, and CLS-D prevalence increased markedly with
greater numbers of new sexual partners (Fig. 1).
Among 2163 MSM with information on self-reported
ART/viral load, those on ARTwere less likely than those
not on ART to report anal/vaginal sex (61.9% vs. 76.7%),
CLS (36.9% vs. 48.4%) and CLS-D (14.3% vs. 18.8%) in
the past three months, P< 0.05 for all (x2 tests). MSM on
ARTwere less likely than those not on ART to have: STI(9.9% vs. 16.7%) or group sex (19.6% vs. 28.6%) in the
past three months, or 10 or more new partners in the past
year (24.5% vs. 36.2%), P< 0.001 for all. Among MSM
on ART, CLS-D prevalence was higher among those
with undetectable self-reported viral load than without
(15.2% vs. 9.8%, P¼ 0.014, Table 3a). However CLS-D
prevalence among MSM not on ART (18.8%) was higher
than for both ‘on ART’ groups. Table 3a also shows
associations with other factors. Prevalence of CLS-D
declined with older age, and with longer time since HIV
diagnosis, and was higher among MSM without an HIV-
positive stable partner. CLS-D was associated with higher
alcohol consumption, and strongly with recreational drug
use, but not with ethnicity, birth in the United Kingdom,
education, employment status, financial hardship, reli-
gion, smoking status or CD4þ cell count. Patterns of
association were similar with all CLS.
After adjustment for socio-demographic and HIV-related
factors, compared with MSM on ARTwith undetectable
self-reported viral load, those on ARTwithout undetect-
able self-reported viral load had significantly lower
CLS-D prevalence [adjusted prevalence ratio (95% CI):
0.66 (0.45, 0.95)], whereas those not on ART had similar
prevalence [1.08 (0.78, 1.49)] (Table 4a). Attenuation of
this latter effect (‘not on ART’ vs. ‘ART with
undetectable self-reported viral load’) was primarily
because of adjustment for time with diagnosed HIV. The
significant difference in CLS-D between the two ‘on
ART’ groups persisted after additional adjustment for
alcohol and recreational drug use (Table 4a).
Sexual behaviour and association with self-
reported antiretroviral treatment/viral load
among heterosexual men and women
Table 2 shows sexual behaviour among heterosexual men
and women. Of 360 heterosexual men, 226 (62.8%), 83
(23.1%) and 23 (6.4%) reported vaginal/anal sex, CLS and
CLS-D respectively in the past 3 months. Among the 629
women, corresponding numbers were: 316 (50.2%), 133
(21.1%) and 67 (10.7%). Inclusion of ‘possible’ CLS-D
made little difference to prevalence. Patterns of sexual
behaviour among heterosexual participants differed from
MSM: the vast majority had sex with a single partner,
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Table 2. Sexual behaviour according to gender/sexual orientation, among 3178 individuals diagnosed with HIV more than 3 months ago.
MSM N¼2189 Heterosexual men N¼360 Women N¼629
Sexual behaviour in past 3 months
(N, denominator across all groups)a n (%) n (%) n (%)
Any anal or vaginal sex (N¼3178) 1392 (63.6%)i 226 (62.8) 316 (50.2)
Number of anal/vaginal sexual partners (N¼1827c who had sex)
1 594 (44.7%) 194 (90.7%) 279 (98.2%)
2–4 379 (28.5%) 19 (8.9%) 5 (1.8%)
5–9 171 (12.9%) 1 (0.5%) 
10–19 106 (8.0%)  
20 79 (5.9%)  
Number not given 63 12 32
Condomless sex (CLS) (N¼3178) 836 (38.2%) 83 (23.1%) 133 (21.1%)
95% confidence interval (CI) (36.1%, 40.3%) (18.8%, 27.8%) (18.0%, 24.5%)
CLS with HIV serodifferent partner (CLS-D) 326 (14.9%) 23 (6.4) 67 (10.7)
95% confidence interval (CI) (13.4%, 16.5%) (4.1%, 9.4%) (8.4%, 13.3%)
CLS-D including ‘possible’ casesb 357 (16.3%) 25 (6.9) 68 (10.8)
95% confidence interval (CI) (14.8%, 17.9%) (4.5%, 10.1%) (8.5%, 13.5%)
Number CLS-D partners, (N¼403d who had CLS-D)
1 180 (57.5) 21 (91.3) 67 (100.0)
2–4 90 (28.8) 2 (8.7) –
5–9 22 (7.0) – –
10 21 (6.7) – –
Number not given 13 – –
Total number times CLS-D, (N¼375 e who had CLS-D)
Once 95 (30.6%) 1 (7.7%) 14 (26.9%)
2–10 times 155 (50.0%) 11 (84.6%) 26 (50.0%)
11 times 60 (19.4%) 1 (7.7%) 12 (23.1%)
Number of times not given 16 10 15
Type CLS-D partner(s), (N¼408f who had CLS-D)
Long-term partner only 76 (23.9%) 18 (78.3%) 63 (94.0%)
Long-term partner and other partner(s) 19 (6.0%) – –
Other partner(s) 223 (70.1%) 5 (21.7%) 4 (6.0%)
Missing partner type 8 – –
Type CLS-D sex (for MSM only), (N¼314 MSMg who had CLS-D)
CLS-D anal sex with men
Insertive anal sex with ejaculation 88 (28.0%)
Insertive anal sex without ejaculation 92 (29.3%)
Receptive anal sex 126 (40.1%)
CLS-D with women only 8 (2.5%)
CLS-D anal sex with men, missing type 12
Sexually transmitted infection diagnosed in past
3 months, (N¼3178)
235 (10.7%) 16 (4.4%) 35 (5.6%)
Had group sexh in past 3 months, (N¼3178) 453 (20.7%) 2 (0.6%) 5 (0.8%)
10 new sexual partners in past year, (N¼2913) 533 (25.9%) 0 (0%) 1 (0.2%)
Believe that HIV transmission risk very low
indicated as reason for not using condom
on last occasion of CLS-D, (N¼416 who
had CLS-D)
122 (37.4%) 8 (34.8%) 27 (40.3%)
Transmission risk belief scorej, (N¼3129)
2: If viral load undetectable, condom not
needed to prevent HIV transmission
99 (4.6%) 35 (10.0%) 47 (7.7%)
1: Less infectious if viral load undetectable
(but does not agree with 2 above)
1023 (47.3%) 122 (34.8%) 233 (38.0%)
0: Does not agree with either of 1 or 2 above 1043 (48.2%) 194 (55.3%) 333 (54.3%)
aAll variables relate to a 3-month recall period unless otherwise indicated.
bIncludes those who reported CLS, but did not specify whether with HIV serodifferent or concordant status partner(s).
cOf all those reporting anal/vaginal sex; percentages are given of 1329, 214 and 284 non-missing values for MSM, heterosexual men, women.
dOf all those reporting CLS-D; percentages are given of 313 non-missing values for MSM.
eOf all those reporting CLS-D; percentages are given of 310, 13 and 52 all non-missing values for MSM, heterosexual men, women.
fOf all those reporting CLS-D; percentages are given of 318 non-missing values for MSM.
gOf all those reporting CLS-D; percentages are given of 314 non-missing values for MSM.
hSex with more than one person on the same occasion.
i20 had sex with both men and women, and 12 had sex with women only.
jHierarchical classification.
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Fig. 1. Prevalence of condomless sex (CLS) and condomless
sex with HIV-serodifferent partner (CLS-D) in the past three
months according to number of new sexual partners
reported in the past year, among MSM diagnosed with
HIVmore than 3months ago.N, 2058 MSM with information
on number of new sexual partners in past year. Among 131
MSM with missing data on new sexual partners, prevalence of
CLS-D and CLS was 14.5 and 31.3%, respectively.CLS-D was usually with a long-term partner, recent STI
was less common and prevalence of group sex and
multiple partners was very low.
Among 351 heterosexual men with information on self-
reported ART/viral load, there were no significant
differences between those on ART vs. not on ART in
prevalence of vaginal/anal sex (63.6% vs. 70.8%), CLS
(23.9% vs. 16.7%) and CSL-D (6.4% vs. 4.2%) in the past
3 months. Similarly, among 611 women, ART was not
associated with vaginal/anal sex (50.6% vs. 54.4% for on
versus not on ART), CLS (21.4% vs. 23.5%) or CLS-D
(11.2% vs. 8.8%) (P> 0.3 for all, x2/Fisher’s exact test).
Table 3b shows associations for all heterosexual partici-
pants combined. Self-reported ART/viral load was not
associated with CLS-D. CLS-D was associated with
younger age, birth in the United Kingdom, non-black
ethnicity, university education, not having a recent HIV
diagnosis, higher CD4þ cell count and tended to be
associated with greater financial security. CLS-D
prevalence was much lower among the majority of
individuals who identified with a religion than the
minority who did not, and much higher among people
with an HIV-negative/unknown status stable partner.
CLS-D was associated with recreational drug use, but
not with smoking or alcohol use. Patterns of association
were broadly similar with all CLS. There remained no
significant association of self-reported ART/viral load
with CLS-D among heterosexual individuals in adjusted
models (Table 4b).
Transmission risk beliefs
Table 2 shows that the vast majority of participants
believed in the need for condoms, even with undetectable
viral load, and approximately half did not agree thatundetectable viral load reduced infectiousness. However,
of all 416 participants who reported CLS-D, just over a
third (37.7%) gave ‘belief that transmission risk is very
low’ as one reason for not using a condom. This
percentage was 41.9% among participants on ART with
undetectable self-reported viral load, compared with
23.1% among those on ART without undetectable self-
reported viral load, and 27.9% among those not on ART
(P¼ 0.008, x2).
Self-reported antiretroviral treatment/viral load
and HIV-transmission risk sex
Among 2142 participants on ART who reported
undetectable viral load, the vast majority (96.5%;
n¼ 2066) had clinic-recorded viral load 50 copies/ml
or less. Conversely, of all 2389 with clinic viral load
50 copies/ml or less, 86.5% had undetectable self-
reported viral load. Prevalence of CLS-D-HIV-risk
(CLS-D together with either ‘not on ART’ or clinic-
recorded viral load >50 copies/ml) was 3.2% (101/3178)
overall, 16.1% (61/379) among those not on ART (by
definition equivalent to CLS-D), 0.6% (14/2154) among
those on ART with undetectable self-reported viral load
(the 14 cases because of CLS-D together with clinic viral
load >50 copies/ml despite undetectable self-reported
viral load), and 4.2% (25/592) among those on ART
without undetectable self-reported viral load. Among
MSM, these proportions were 3.9% (85/2189) overall,
and 18.8% (54/287), 0.8% (12/1569) and 5.9% (18/307)
respectively for the three self-reported ART/viral load
categories. Among heterosexual individuals, correspond-
ing proportions were 1.6% (16/989) overall; 7.6% (7/92),
0.3% (2/585) and 2.5% (7/285) for the self-reported
ART/viral load categories. Therefore, prevalence of
CLS-D-HIV-risk was much lower among people on
ART, and extremely low (<1%) among those on ART
with undetectable self-reported viral load.
Sensitivity analyses
Among MSM, when defining CLS-D to include possible
CLS-D, adjusted prevalence ratios (95% CI) from model
2 were: 0.74 (0.53, 1.04) for ‘ARTwithout undetectable
self-reported viral load’ and 1.06 (0.78, 1.44) for ‘not on
ART’, compared with ‘ART with undetectable self-
reported viral load’ (global P¼ 0.11). Including only
MSM who had sex in the past 3 months, corresponding
adjusted prevalence ratios (95% CI) were 0.68 (0.48, 0.96)
and 0.98 (0.72, 1.33) (P¼ 0.042). Among MSM
diagnosed less than 5 years ago, adjusted prevalence
ratios (95% CI) were 0.22 (0.08, 0.59) for ‘ARTwithout
undetectable self-reported viral load’, and 0.70 (0.46,
1.07) for ‘not on ART’, compared with ‘ART with
undetectable self-reported viral load’. Among MSM
diagnosed 5 years ago or more, corresponding adjusted
prevalence ratios (95% CI) were 0.88 (0.59, 1.31) and
1.60 (1.10, 2.33); this interaction was significant
(P¼ 0.001). Among heterosexual individuals, there
was no significant association between self-reported
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Table 3. Condomless sex with HIV-serodifferent partner (CLS-D), and all condomless sex (CLS), in the past three months, according to self-
reportedART/viral load status and other factors, among 3178 individuals diagnosedwithHIVmore than 3months ago: (a) 2189MSMand (b) 989
heterosexual men and women.
(a) MSM (N¼2189)
(b) Heterosexual men and
women (N¼989)
n (%) n (%) n (%) n (%)
N CLS-D CLS N CLS-D CLS
Self-reported ART status (1)
Not on ART 287 54 (18.8) 139 (48.4) 92 7 (7.6) 20 (21.7)
On ART 1876 268 (14.3) 692 (36.9) 870 82 (9.4) 194 (22.3)
P¼0.045 P<0.001 P¼0.57 P¼0.90
Self-reported ART status (2)
Never taken ART 253 42 (16.6) 123 (48.6) 61 6 (9.8) 16 (26.2)
Ever taken ART 1910 280 (14.7) 708 (37.1) 901 83 (9.2) 198 (22.0)
P¼0.42 P<0.001 P¼0.87 P¼0.44
Self-reported ART status (3)
Never taken ART 253 42 (16.6) 123 (48.6) 61 6 (9.8) 16 (26.2)
Stopped ART 34 12 (35.3) 16 (47.1) 31 1 (3.2) 4 (12.9)
On ART 1876 268 (14.3) 692 (36.9) 870 82 (9.4) 194 (22.3)
P¼0.002 P<0.001 P¼0.50 P¼0.35
Self-reported ART and viral load status
Not on ART 287 54 (18.8) 139 (48.4) 92 7 (7.6) 20 (21.7)
On ART, viral load50 copies/ml 1569 238 (15.2) 594 (37.9) 585 60 (10.3) 137 (23.4)
On ART, viral load>50 copies/ml or unknowna 307 30 (9.8) 98 (31.9) 285 22 (7.7) 57 (20.0)
P¼0.007 P<0.001 P¼0.41 P¼0.52
Age group (years)
<30 96 23 (24.0) 56 (58.3) 63 8 (12.7) 15 (23.8)
30–39 487 75 (15.4) 233 (47.8) 233 27 (11.6) 57 (24.5)
40–49 929 144 (15.5) 354 (38.1) 415 33 (8.0) 94 (22.7)
50–59 503 62 (12.3) 154 (30.6) 174 18 (10.3) 36 (20.7)
60 152 18 (11.8) 33 (21.7) 60 1 (1.7) 4 (6.7)
P¼0.008# P<0.001# P¼0.049# P¼0.020#
Ethnicity
White 1931 282 (14.6) 739 (38.3) 236 29 (12.3) 65 (27.5)
Black African 21 3 (14.3) 4 (19.1) 580 46 (7.9) 123 (21.2)
Black other 54 8 (14.8) 23 (42.6) 69 3 (4.3) 9 (13.0)
Other/missing 183 33 (18.0) 70 (38.3) 104 12 (11.5) 19 (18.3)
P¼0.67 P¼0.29 P¼0.090 P¼0.036
UK birth
Yes 1532 226 (14.8) 583 (38.1) 208 27 (13.0) 61 (29.3)
No 629 96 (15.3) 244 (38.8) 736 58 (7.9) 146 (19.8)
P¼0.76 P¼0.75 P¼0.023 P¼0.004
Education
University 954 149 (15.6) 391 (41.0) 324 38 (11.7) 87 (26.9)
Other/missing 1235 177 (14.3) 445 (36.0) 665 52 (7.8) 129 (19.4)
P¼0.40 P¼0.018 P¼0.045 P¼0.008
Employment status
Employed (full or part time) 1326 211 (15.9) 562 (42.4) 440 49 (11.1) 119 (27.1)
Unemployed 309 46 (14.9) 109 (35.3) 254 19 (7.5) 53 (20.9)
Not working: sick or disabled 316 42 (13.3) 104 (32.9) 100 7 (7.0) 11 (11.0)
Other (student, looking after home, retired, other) 203 22 (10.8) 51 (25.1) 149 11 (7.4) 26 (17.4)
P¼0.23 P<0.001 P¼0.25 P¼0.002
Money for basic needs?
Always 1116 164 (14.7) 431 (38.6) 230 26 (11.3) 57 (24.8)
Mostly 597 85 (14.2) 223 (37.4) 226 25 (11.1) 53 (23.5)
Sometimes 277 40 (14.4) 108 (39.0) 279 17 (6.1) 61 (21.9)
No 173 32 (18.5) 65 (37.6) 218 18 (8.3) 37 (17.0)
P¼0.40# P¼0.83# P¼0.082# P¼0.045#
Identify with a religion?
Yes 934 144 (15.4) 342 (36.6) 833 61 (7.3) 163 (19.6)
No/missing 1255 182 (14.5) 494 (39.4) 156 29 (18.6) 53 (34.0)
P¼0.55 P¼0.19 P<0.001 P<0.001
Time since HIV diagnosis
3 months to 1.9 years 184 29 (15.8) 72 (39.1) 109 4 (3.7) 18 (16.5)
2–4.9 years 338 57 (16.9) 157 (46.5) 160 17 (10.6) 36 (22.5)
5–9.9 years 550 96 (17.5) 240 (43.6) 343 33 (9.6) 80 (23.3)
10–14.9 years 461 69 (15.0) 168 (36.4) 186 16 (8.6) 37 (19.9)
15–19.9 years 376 47 (12.5) 126 (33.5) 112 11 (9.8) 25 (22.3)
20 years 268 26 (9.7) 69 (25.7) 63 9 (14.3) 17 (27.0)
P¼0.005# P<0.001# P¼0.11# P¼0.31#
P¼0.033d P¼0.15 d
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Table 3 (continued )
(a) MSM (N¼2189)
(b) Heterosexual men and
women (N¼989)
n (%) n (%) n (%) n (%)
N CLS-D CLS N CLS-D CLS
Partner status
HIVþ stable partner 512 47 (9.2) 309 (60.4) 234 2 (0.9) 106 (45.3)
HIV- or HIV-unknown status stable partner 674 141 (20.9) 198 (29.4) 353 78 (22.1) 95 (26.9)
No stable partner 987 136 (13.8) 326 (33.0) 394 10 (2.5) 15 (3.8)
P<0.001 P<0.001 P<0.001 P<0.001
Current smoker
No/missing 1377 218 (15.8) 506 (36.8) 814 73 (9.0) 172 (21.1)
Yes 812 108 (13.3) 330 (40.8) 175 17 (9.7) 44 (25.1)
P¼0.11 P¼0.070 P¼0.76 P¼0.24
Higher alcohol consumptionb
No/missing 1821 251 (13.8) 684 (37.7) 933 86 (9.2) 201 (21.5)
Yes 368 75 (20.4) 152 (41.6) 56 4 (7.1) 15 (26.8)
P¼0.001 P¼0.18 P¼0.60 P¼0.36
Number of recreational drugs used in past 3 months
None/missing 1078 103 (9.6) 259 (24.0) 888 73 (8.2) 183 (20.6)
1 364 51 (14.0) 119 (32.7) 72 13 (18.1) 26 (36.1)
2–3 403 84 (20.8) 204 (50.6) 28 4 (14.3) 7 (25.0)
4 344 88 (25.6) 254 (73.8) 1 0 (0) 0 (0)
P<0.001# P<0.001# P¼0.004d P¼0.005d
Clinic-recorded CD4þ cell count (cells/ml)c
<200 77 11 (14.3) 21 (27.3) 72 1 (1.4) 9 (12.5)
200–349 240 32 (13.3) 80 (33.3) 166 12 (7.2) 32 (19.3)
250–499 538 79 (14.7) 215 (40.0) 234 19 (8.1) 51 (21.8)
500 1320 201 (15.2) 516 (39.1) 508 57 (11.2) 121 (23.8)
P¼0.49# P¼0.033# P¼0.004# P¼0.026#
Clinic-recorded viral load (copies/ml)c
50 1694 243 (14.3) 617 (36.4) 767 77 (10.0) 173 (22.6)
>50 481 82 (17.1) 217 (45.1) 215 13 (6.1) 42 (19.5)
P¼0.14 P<0.001 P¼0.073 P¼0.34
Denominators vary because of missing values. Self-reported ART status missing for 53 participants (26 MSM, nine heterosexual men and 18
women). Prevalence of CLS-D and CLS among participants with missing current ART status: 15.4 and 19.2% for 26 MSM; 3.7 and 7.4% for 27
heterosexual men and women. Univariate P values by x2 tests.
#x2 tests for trend.
aIncludes ‘do not know’ viral load level and missing response.
bScore of 6 or more on modified WHO AUDIT C questionnaire (using first two questions only).
cLatest clinic-recorded value that participant had been informed of.
dAmong heterosexuals, for time with diagnosed HIV, P value corresponds to comparison of ‘3 months to 1.9 years’ with ‘2 years or more’, using x2
test. For recreational drug use, P value corresponds to comparison of ‘no drug use’ with ‘drug use’, using x2 test.ART/viral load and CLS-D for sensitivity analyses a–c
(data not shown).Discussion
In this large multicentre study of people attending HIV
clinics in the United Kingdom in 2011/12, use of ART
was not associated with higher prevalence of CLS-D.
Among MSM, those on ART had moderately lower
prevalence of CLS-D than those not on ART, although
this association was not independent of time since HIV
diagnosis. Among MSM on ART, those who reported
undetectable viral load had higher levels of CLS-D than
those who did not, but CLS-D prevalence in both ‘on
ART’ groups was lower than for MSM not on ART.
Among heterosexual men and women, self-reported
ART/viral load was not significantly associated withCLS-D. Patterns were similar for CLS overall. The
prevalence of CLS-D-HIV-risk was low in the study
population overall, and extremely low among those on
ART with undetectable self-reported viral load.
With few exceptions [18,21,23], previous epidemiolo-
gical studies [19,20,22–26,28–33] have found either no
association of CLS-D with ART use and/or suppressed
viral load, or that people on ART had somewhat lower
levels of CLS-D. Similarly, a randomized comparison
within the SMART trial (2002–2006) found that starting
ART led to a reduction in CLS-D in the short term [27].
The most recent observational study used data from 2009,
a few years prior to ASTRA. Interview-assessed sexual
behaviour was linked to recorded viral load among a large
sample of United States’ HIV outpatients (Medical
Monitoring Project) [33]. Self-reported viral load was
not assessed. Similar to ASTRA results comparing ‘on
ART’ with ‘not on ART’, the United States’ study found
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’.that individuals with viral load suppression had lower
levels of sex, CLS, and CLS-D than those without; the
association was significant only for MSM.
For MSM on ART in ASTRA, the prevalence of CLS-D
was higher among those who reported undetectable viral
load than among those who did not. This modest
difference remained after adjustment for other factors,
and among the subgroup of MSM who had recent sex
(sensitivity analysis b), therefore was not due to those on
ART being less likely to be sexually active. The difference
was particularly marked among those more recently
diagnosed (sensitivity analysis c). Although there may be
other differences between the two ‘on ART’ groups, one
plausible explanation is that some MSM were choosing
not to use a condom with HIV-serodifferent partners
because of knowledge of very low infectiousness based on
their perceived viral load. Consistent with this, of all
participants who reported CLS-D, belief that transmission
risk was low was more frequently a reason for not using
condoms among those with undetectable self-reported
viral load than those without. However, if knowledge of
viral load was influencing sexual behaviour among MSM,
the effect appeared modest, because levels of CLS-D
among those on ART with undetectable self-reported
viral load did not exceed those for men not on ART.
Prevalence estimates of CLS-D among MSM (15%) and
heterosexual men (6%) and women (11%) with HIV in
ASTRA are similar to those from two clinic-based studies
in the United Kingdom in 2004–2005 using an identical
definition (20 and 15% among 758 [22] and 451 [29]
MSM, respectively; less than 10% among heterosexual
men and women [22,29]), and from the European
START trial participants at baseline: 15, 3 and 10% in the
past 2 months for 1518 MSM, 207 heterosexual men and
138 women with HIV not taking ART (recently
diagnosed participants were included) [41]. The START
analysis found no significant trend in baseline CLS-D
prevalence over the recruitment period (2009–2013).
Taken together these results suggest levels of CLS-D
among people with HIV have remained fairly stable in the
past decade, emphasising further that any change related
to new messages about ‘safe sex’ has not been significant.
Comparison with other studies is complicated by
different recall periods and sampling frames: internet
and venue-based studies tend to yield higher CLS-D
estimates among HIV-positive MSM [42,43], which may
be because of selection bias. Consistent with other studies
[41,44–46], ASTRA suggests that perceived risk-
reduction strategies (withdrawal before ejaculation and
being the receptive partner) are commonly used among
HIV-positive MSM having CLS-D.
Among MSM in ASTRA, CLS-D prevalence was lower
with longer time since diagnosis, and higher among
younger men, those without an HIV-positive stable
partner, and those with higher alcohol and drug use, but
1756 AIDS 2016, Vol 30 No 11CLS-D was not linked to socio-economic status.
Similarly, among MSM in START, CLS-D was not
associated with education level [41]. We have previously
described the strong link between polydrug use and
CLS/CLS-D among MSM [40], in part reflecting use of
‘chemsex’ [47]. Among heterosexual individuals in
ASTRA, factors associated with CLS-D included white
ethnicity, and higher socio-economic status in unadjusted
analysis. In contrast, among heterosexual individuals in
START, CLS-D tended to be associated with non-white
ethnicity and lower education in unadjusted analysis [41].
START had a diverse international population; socio-
demographic effects on sexual behaviour may vary across
cultural settings. Among heterosexuals in ASTRA,
female sex, not having a recent HIV diagnosis, not
identifying with a religion and recreational drug use were
independent correlates of CLS-D, but the dominant
association was with having an HIV-negative stable
partner – this was the context of CLS-D for most
heterosexual men and women who reported it. There
may be specific issues relating to CLS-D in this context,
such as desire for conception, or mutuality of decision
making about condom use.
ASTRA is the largest questionnaire study of sexual
behaviour among people living with HIV in the United
Kingdom; although power to assess associations among
heterosexual men and women separately was limited.
Participants were reassured that questionnaire responses
were confidential and would not be seen by clinic staff.
Nevertheless, self-reported behaviour and attitudes may
be subject to errors and social desirability bias.
What are the implications of these results for HIV-
transmission? The prevalence of ‘HIV-transmission risk
sex’ was much lower among those on ART vs. not on
ART (1.4% vs 16.1%), and less than 1% among those on
ART with undetectable self-reported viral load. Even if
the ASTRA results do indicate the start of a trend of
increasingly higher levels of CLS-D with perceived
undetectable viral load (among MSM or the HIV-
diagnosed population overall), prevalence of CLS-D-
HIV-risk will likely continue to remain far lower among
those on ART with undetectable self-reported viral load
than among those not on ART. This is because of the
effectiveness of ART and the apparent high accuracy of
self-reported undetectable viral load status in this
population. These results highlight the importance, as
ART use expands, of promoting sustained high adher-
ence, regular viral load testing, and on-going awareness of
personal viral load level. It is also important to note that
the definition of CLS-D-HIV-risk used here is based on
the single clinic viral load measurement collected for all
ASTRA participants, assumes elimination of risk with
viral suppression on ART (as assumed with condom use),
and does not incorporate factors such as self-reported
ART non-adherence or presence of other STIs, the
additional impact of which are uncertain [13,48].In terms of transmission of other STIs, CLS overall is the
most relevant measure. Similar to CLS-D, CLS preva-
lence among MSM was highest for those not on ART
with no significant difference by ART use among
heterosexual individuals. Therefore these data give little
suggestion that expansion of ARTuse will have a negative
impact on STI transmission. Nevertheless, the high
prevalence of CLS compared with CLS-D-HIV risk, and
the possibility that levels of CLS among those with
undetectable self-reported viral load may continue to
increase, emphasise the importance of ongoing pro-
motion of condom use, STI prevention and testing
among people with HIV.
The ASTRA study was planned in the period following
the Swiss statement, which was then hugely controversial
[49]. During recruitment, results were released from
HPTN 052 [12]; PARTNER results were first presented
after completion of ASTRA [13]. During this period
United Kingdom [37] and other [50,51] treatment
guidelines were changed to recommend discussing with
HIV-positive people the beneficial effect of ART on
infectiousness. The extent to which, and the rapidity with
which, these findings and recommendations may influence
the sexual behaviour of people with HIV [52], or change
the long-standing culture of condom use [3], is unclear.
With increasing use of early ART, it will be important to
continue monitoring the association between ART and
CLS, not only to understand the impact on HIV
transmission, but also to assess implications for transmission
of hepatitis C and other STIs.
In conclusion, among people with HIV in the United
Kingdom, use of ART was not associated with increased
prevalence of CLS or CLS-D, and was associated with
greatly reduced prevalence of HIV-transmission risk sex.
Although there was evidence that perceived undetectable
viral load may influence condom use among MSM, any
such effect was modest at the time of the study, and would
not undermine the effect of early ART on HIV/STI
transmission. These results support the prevention role of
ART offered to all people with HIV, and emphasise the
need to focus on HIV/STI prevention among those not
on ART.Acknowledgements
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